Adverse events in chronic hemodialysis patients receiving intravenous iron dextran - A comparison of two products

American Journal of Nephrology

Volumn 20, Issue 6, 2000, Pages 455-462

  McCarthy, James T ^a   Regnier, Cynthia E ^a   Loebertmann, Carrie L ^a   Bergstralh, Erik J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adverse events; Adverse reactions; Dialysis; Hemodialysis; Iron; Iron dextran; Side effects

Indexed keywords

FERRITIN; IRON DEXTRAN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; DIABETES MELLITUS; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; KIDNEY FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; SKIN DISEASE; SYSTEMIC DISEASE; TREATMENT OUTCOME; UNITED STATES;

AGED; ANEMIA; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HUMANS; INFUSIONS, INTRAVENOUS; IRON-DEXTRAN COMPLEX; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0034525862     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000046199     Document Type: Article

References (26)

1. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure
2. An indistinct balance: The safety and efficacy of parenteral iron therapy
3. Beneficial effects of iron therapy in renal failure patients on hemodialysis
4. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients
5. Strategies for iron supplementation: Oral versus intravenous
6. Parenteral iron: Pharmacology and clinical use
7. A study of parenteral iron regimens in hemodialysis patients
8. Iron management in end-stage renal disease
9. Reduction in recombinant human erythropoietin doses by the uses of chronic intravenous iron supplementation
10. Safety aspects of parenteral iron in patients with end-stage renal disease
11. Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: A prospective analysis and comparison of two agents
12. Development and comparison of iron dextran products
13. Anaphylaxis associated with the use of dextran
14. Dextran-induced anaphylaxis
15. Longitudinal data analysis using generalized linear models
16. Toxicity of parenteral iron dextran therapy
17. The safety of intravenous iron dextran in hemodialysis patients
18. Randomized cross-over study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients
19. Intravenous iron dextran in clinical medicine
20. Clinical use of the total dose intravenous infusion of iron dextran
21. Intravenous iron dextran therapy
22. Suspected iron dextran-related adverse drug events in hemodialysis patients
23. Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis
24. Dextran antibodies, complement conversion and circulating immune complexes after intravenous iron dextran therapy in dialyzed patients
25. Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran
26. Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans